← Leaderboards
Cezary Marcinkiewicz
Temple University
$2,133,547
Attributed
$2,133,547
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $305.3K · FY2005–12$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
'11
'12
Funding mix
By agency
NIH$2,133,547 · 2
By mechanism
R01$2,133,547 · 2
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Cell Proliferation”
- John M Lachin · George Washington University$118,921,924
- David M Nathan · Massachusetts Institute Of Technology$118,921,924
- David Heimbrook · Leidos Biomedical Research, Inc.$103,164,048
- Timothy J Eberlein · Washington University$49,931,668
- Deirdre R. Meldrum · University Of Washington$37,202,510
- Robert A Weinberg · Whitehead Institute For Biomedical Res$32,735,166
Research focus
Cell ProliferationCell MotilityAngiogenesisIntegrinsInvestigationIn VitroIn VivoEnzyme-Linked Immunosorbent AssayInhibitor/AntagonistGrowthBlood CapillariesDisintegrinsAmino AcidsAntibodiesEndothelial CellsIntegrin BindingBinding SitesCellsAdhesionsBinding (Molecular Function)FamilyBaseAnalogLead
Grant awards (8)
Interaction of thrombospondin-1 with alpha9beta1 integrin in glioma angiogenesis$301,913
R01 · FY2012 · CA · contact PI
Interaction of thrombospondin-1 with alpha9beta1 integrin in glioma angiogenesis$301,913
R01 · FY2011 · CA · contact PI
Interaction of thrombospondin-1 with alpha9beta1 integrin in glioma angiogenesis$305,259
R01 · FY2010 · CA · contact PI
Interaction of thrombospondin-1 with alpha9beta1 integrin in glioma angiogenesis$290,500
R01 · FY2009 · CA · contact PI
Targeting alfa 1beta1 integrin in cancer development$229,628
R01 · FY2007 · CA · contact PI
Targeting alfa 1beta1 integrin in cancer development$236,484
R01 · FY2006 · CA · contact PI
Targeting alfa 1beta1 integrin in cancer development$242,175
R01 · FY2005 · CA
Targeting alfa 1beta1 integrin in cancer development$225,675
R01 · FY2004 · CA